A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: Virus and prion reduction capacity

Vox Sanguinis

Volumn 94, Issue 3, 2008, Pages 184-192

  Poelsler, G ^a   Berting, A ^a   Kindermann, J ^a   Spruth, M ^a   Hammerle T ^a   Teschner, W ^a   Schwarz, H P ^a   Kreil, T R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Blood borne; Immunoglobulin; Pathogen; Prion; TSE; Viral safety

Indexed keywords

ALCOHOL; DETERGENT; GAMMAGARD LIQUID; IMMUNOGLOBULIN; KIOVIG; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BOVINE DIARRHEA VIRUS; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG SAFETY; ENCEPHALOMYOCARDITIS VIRUS; HEATING; HEPATITIS A VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS A H5N1; NANOFILTRATION; NONHUMAN; PARVOVIRUS; PRION; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; VIRAL CONTAMINATION; VIRUS INACTIVATION; VIRUS INFECTIVITY; WEST NILE FLAVIVIRUS; WESTERN BLOTTING;

CYTOPATHOGENIC EFFECT, VIRAL; DETERGENTS; DRUG CONTAMINATION; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULINS, INTRAVENOUS; MICROPORE FILTERS; POLYMERASE CHAIN REACTION; PRIONS; SAFETY; SOLVENTS; TEMPERATURE; ULTRAFILTRATION; VIRUS INACTIVATION; VIRUSES;

EID: 40749088877     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2007.01016.x     Document Type: Article

References (29)

1. Burnouf T, Radosevich M : Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000 14 : 94 110
2. EMEA : Note for Guidance on the Warning on Transmissible Agents in Summary of Product Characteristics (SPCs) and Package Leaflets for Plasma-derived Medicinal Products, CPMP/BPWG/BWP/561/03, 2003. Available at http://www.tga.gov.au/docs/pdf/euguide/bpwg/056103en.pdf
3. Burnouf T, Padilla A : Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006 13 : 320 328
4. EMEA : CPMP Note for Guidance on Plasma Derived Medicinal Products, CPMP/BWP/269/95, 1996. Available at http://www.emea.europa.eu/pdfs/human/bwp/ 026995en.pdf
5. Mitra G, Dobkin MB, Wong MF, Mozen MM : Virus inactivation/elimination in therapeutic protein concentrates. Curr Stud Hematol Blood Transfus 1989 : 34 43
6. Burnouf T : Chromatographic removal of viruses from plasma derivatives. Dev Biol Stand 1993 81 : 199 209
7. Teschner W, Butterweck HA, Auer W, Muchitsch EM, Weber A, Liu SL, Wah PS, Schwarz HP : A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process. Vox Sang 2007 92 : 42 55
8. Kreil TR, Wieser A, Berting A, Spruth M, Medek C, Polsler G, Gaida T, Hammerle T, Teschner W, Schwarz HP, Barrett PN : Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives. Transfusion 2006 46 : 1143 1151
9. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, Collinge J : Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001 358 : 171 180
10. EMEA : CPMP Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses, CPMP/BWP/268/95/Rev, 1996. Available at http://www.emea. europa.eu/pdfs/human/bwp/026895en.pdf
11. Horowitz B, Prince AM, Horowitz MS, Watklevicz C : Viral safety of solvent-detergent treated blood products. Dev Biol Stand 1993 81 : 147 161
12. Boulay F, Doms RW, Wilson I, Helenius A : The influenza hemagglutinin precursor as an acid-sensitive probe of the biosynthetic pathway. EMBO J 1987 6 : 2643 2650
13. Cai K, Miller JL, Stenland CJ, Gilligan KJ, Hartwell RC, Terry JC, Evans-Storms RB, Rubenstein R, Petteway SR Jr., Lee DC : Solvent-dependent precipitation of prion protein. Biochim Biophys Acta 2002 1597 : 28 35
14. FDA : (U.S.) National Institute of Allergy and Infectious Diseases (NIAID), Executive Summary of the Expert Panel on the Safety and Efficacy of Immunoglobulin Products, April 6-7, 1998. Available at http://www.niaid.nih.gov/ dait/ivig1.html#A
15. Farshid M, Taffs RE, Scott D, Asher DM, Brorson K : The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Curr Opin Biotechnol 2005 16 : 561 567
16. Collins SJ, Lawson VA, Masters CL : Transmissible spongiform encephalopathies. Lancet 2004 363 : 51 61
17. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG : Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006 91 : 221 230
18. Farrugia A : The mantra of blood safety: time for a new tune? Vox Sang 2004 86 : 1 7
19. Roberts P : Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Biologicals 2000 28 : 29 32
20. Kreil TR, Unger U, Orth SM, Petutschnig G, Kistner O, Poelsler G, Berting A : H5N1 influenza virus and the safety of plasma products. Transfusion 2007 47 : 452 459
21. Kreil TR, Berting A, Kistner O, Kindermann J : West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003 43 : 1023 1028
22. Roberts PL, Dunkerley C : Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate. Vox Sang 2003 84 : 170 175
23. Troccoli NM, McIver J, Losikoff A, Poiley J : Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 1998 26 : 321 329
24. Omar A, Kempf C : Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion 2002 42 : 1005 1010
25. Omar A, Kempf C, Immelmann A, Rentsch M, Morgenthaler JJ : Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation. Transfusion 1996 36 : 866 872
26. Hamalainen E, Suomela H, Ukkonen P : Virus inactivation during intravenous immunoglobulin production. Vox Sang 1992 63 : 6 11
27. Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG : Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 2004 32 : 1 10
28. Van Holten RW, Autenrieth SM : Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang 2003 85 : 20 24
29. Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR Jr. : A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001 41 : 449 455